Cargando…
Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy
Autores principales: | Gadhoum, S Z, Madhoun, N Y, Abuelela, A F, Merzaban, J S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155032/ https://www.ncbi.nlm.nih.gov/pubmed/27499140 http://dx.doi.org/10.1038/leu.2016.221 |
Ejemplares similares
-
Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018) -
The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling
por: Merhi, Ahmad, et al.
Publicado: (2017) -
mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Ding, Xiaolei, et al.
Publicado: (2016)